Sinoway Industrial Co., Ltd.

Linagliptin 668270-12-0 Linagliptin 668270-12-0

Linagliptin 668270-12-0
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic information of Linagliptin:

Name

Linagliptin

Alias

8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione

CAS NO.

668270-12-0

Molecular Formula

C25H28N8O2

Molecular Weight

472.54

Grade Standard

Medicine grade  / 99% min / GMP application / PMDA / DMF

Package Size

25kg/drum

Storage:

Keep in a well-closed container, protected from light and stored at a temperature of 2 to 8


Use of Linagliptin:

Linagliptin is used to control of blood glucose levels in people with type 2 diabetes by combining diet and exercise. Linagliptin controls glycemic in patients by inhibiting dipeptidyl peptidase-4 (DPP-4).

Compared with other DPP-4 inhibitors, the main advantages of linagliptin are: excellent renal safety and effective reduction of glycated hemoglobin. Lilacitin is mainly excreted in the form of a prototype, and after oral administration, the amount of renal excretion is only 5% of the dose, and even if administered intravenously, only 30.8% is excreted by the kidney, so the patient receiving the treatment does not need Regular examination of liver and kidney function and dose adjustment, all patients can be fixed doses, easy to prescribe.

COA of Linagliptin:

Items

 

Specification

 

Result

 

Assay

 

≥98.5%

 

99.77%

 

Appearance

 

White to light yellow powder

 

Light yellow powder

Loss on drying

≤0.5%

0.38%

Residue on drying

≤0.1%

0.07%

Single impurity

≤0.5%

0.08%

Total impurity

≤1.5%

0.23%



  • Orlistat 96829-58-2
    Basic information of OrlistatNameOrlistatCAS96829-58-2EINECSMolecular FormulaC29H53NO5Molecular Weight495.73Quality Standard USP37/ in-house standarad, 98.5%Package Size5kg/tinBrief IntroductionWhite ... Orlistat 96829-58-2
  • Fusidic Acid 6990-06-3
    Basic information of Fusidic AcidNameFusidic Acid AliasFusidate sodium; Diethanolamine fusidate; FUCIDIN; fusdic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,... Fusidic Acid 6990-06-3
  • Oxaliplatin 61825-94-3
    Basic information of Oxaliplatin :Name OxaliplatinAliastrans-l-diaminocyclohexane oxalatoplatinum; oxalato(1r,2r-cyclohexanediammine)platinum(ii); oxalatoplatin; oxalatoplatinumCAS NO.61825-94-3Molecu... Oxaliplatin 61825-94-3
  • Clopidogrel Besilate 7744256-69-0
    Basic information of Clopidogrel BesilateNameClopidogrel BesilateAlias Clopidogrel benzenesulfonateCAS NO.7744256-69-0Molecular FormulaC21H20ClNO5S2Molecular Weight 465.9702Quality Standard Enterprise... Clopidogrel Besilate 7744256-69-0

MORE_DETAIL Linagliptin 668270-12-0

Basic information of Linagliptin:

Name

Linagliptin

Alias

8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione

CAS NO.

668270-12-0

Molecular Formula

C25H28N8O2

Molecular Weight

472.54

Grade Standard

Medicine grade  / 99% min / GMP application / PMDA / DMF

Package Size

25kg/drum

Storage:

Keep in a well-closed container, protected from light and stored at a temperature of 2 to 8


Use of Linagliptin:

Linagliptin is used to control of blood glucose levels in people with type 2 diabetes by combining diet and exercise. Linagliptin controls glycemic in patients by inhibiting dipeptidyl peptidase-4 (DPP-4).

Compared with other DPP-4 inhibitors, the main advantages of linagliptin are: excellent renal safety and effective reduction of glycated hemoglobin. Lilacitin is mainly excreted in the form of a prototype, and after oral administration, the amount of renal excretion is only 5% of the dose, and even if administered intravenously, only 30.8% is excreted by the kidney, so the patient receiving the treatment does not need Regular examination of liver and kidney function and dose adjustment, all patients can be fixed doses, easy to prescribe.

COA of Linagliptin:

Items

 

Specification

 

Result

 

Assay

 

≥98.5%

 

99.77%

 

Appearance

 

White to light yellow powder

 

Light yellow powder

Loss on drying

≤0.5%

0.38%

Residue on drying

≤0.1%

0.07%

Single impurity

≤0.5%

0.08%

Total impurity

≤1.5%

0.23%


Leave a Message Email Us

We will contact you within 24 hours.

  • TEL:+86-0592-5853819
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//